Ignite Creation Date:
2024-05-06 @ 6:41 PM
Last Modification Date:
2024-10-26 @ 2:52 PM
Study NCT ID:
NCT05744063
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-02-20
First Post:
2023-02-13
Brief Title:
A Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of pHLH in Treatment Experienced Chinese Patients
Sponsor:
Swedish Orphan Biovitrum
Organization:
Swedish Orphan Biovitrum
Organization Data
Organization:
Swedish Orphan Biovitrum
Class:
INDUSTRY
Study ID:
Sobiemapalumab-104
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Swedish Orphan Biovitrum
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None